BioSyntech Appoints Chief Executive Officer
Ms Bertonis has been a management consultant for the last three years, providing strategic and business advice primarily to venture capital groups and private biomedical companies, with a focus on biomaterials, cardiovascular and orthopedics industries. She held the positions of Chief Business Officer and Vice President, Corporate Development for Angiotech Pharmaceuticals from 2000-2006, where she oversaw all of its business and corporate development functions, including mergers and acquisitions, strategic collaborations, and marketing. Prior to joining Angiotech, she held senior business development positions at Guidant and Genzyme, working across a broad spectrum of industries including devices, drugs, combination therapies, gene therapy, cell therapy and bioactive biomaterials.
Topics
Organizations
Other news from the department people
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.